Mirum Drug Shows Promise Against Abnormal Bone Growth in Pediatric Phase 2 Trial

09:15 AM EDT, 10/26/2026 (MT Newswires) -- Mirum Pharmaceuticals (MIRM) said Monday its drug zilurgisertib reduced abnormal bone growth in children with fibrodysplasia ossificans progressiva (FOP) in a phase 2 study. At Week 24, patients receiving the 75 mg dose saw average heterotopic ossification lesion volume decline by 8.09 cubic centimeters, while the placebo group recorded a 9.14 cubic centimeter increase, the company said. No treated patients developed new bone lesions, it said. Mirum added that it plans to submit a supplemental new drug application to expand the treatment's FDA-approved indication to children ages 6 to under 12 in H1 2027.